These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 11154119

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb-IIIa functional activity.
    Jennings LK, White MM, Mandrell TD.
    Thromb Haemost; 1995 Dec; 74(6):1551-6. PubMed ID: 8772236
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S, Lassila R.
    Thromb Res; 2006 Mar; 117(3):291-7. PubMed ID: 15878612
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.
    Dickfeld T, Ruf A, Pogatsa-Murray G, Müller I, Engelmann B, Taubitz W, Fischer J, Meier O, Gawaz M.
    Thromb Res; 2001 Jan 15; 101(2):53-64. PubMed ID: 11342206
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combined defect in membrane expression and activation of platelet GPIIb--IIIa complex without primary sequence abnormalities in myeloproliferative disease.
    Kaplan R, Gabbeta J, Sun L, Mao GF, Rao AK.
    Br J Haematol; 2000 Dec 15; 111(3):954-64. PubMed ID: 11122160
    [Abstract] [Full Text] [Related]

  • 14. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors.
    Jennings LK, White MM.
    Am Heart J; 1998 May 15; 135(5 Pt 2 Su):S179-83. PubMed ID: 9588397
    [Abstract] [Full Text] [Related]

  • 15. Immunological comparisons of integrin alpha IIb beta 3 (GPIIb-IIIa) expressed on platelets and human erythroleukemia cells: evidence for cell specific differences.
    Jennings LK, Slack SM, Wall CD, Mondoro TH.
    Blood Cells Mol Dis; 1996 May 15; 22(1):23-35. PubMed ID: 8807083
    [Abstract] [Full Text] [Related]

  • 16. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B.
    J Pharmacol Exp Ther; 1998 Jun 15; 285(3):1317-26. PubMed ID: 9618439
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 15; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA, Bozarth JM, Forsythe MS, Slee A.
    Cardiovasc Res; 2000 Sep 15; 47(4):819-26. PubMed ID: 10974231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.